A Phase 3 interventional study of Bosentan 62.5 mg and Bosentan 125 mg in Digital Ulcers and Systemic Sclerosis, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.
29 studies on the registry are indexed under digital ulcers; 7 are open to participants now.
This study's enrollment of 188 is above the median of 40 across 23 interventional studies indexed under digital ulcers.
Browse digital ulcers studies →Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
Drug: Bosentan 62.5 mg · Drug: Bosentan 125 mg
The patients received the matching placebo for 24 weeks
Drug: Placebo
Oral tablets containing 62.5 mg of bosentan
Also known as: Ro 47-0203
Oral tablets containing 125 mg of bosentan
Also known as: Ro 47-0203
Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
Time to complete healing of the cardinal ulcer (CU) up to Week 24 in patients with CU healing maintained for 12 weeks
Time frame: 24 weeks
Total number of new digital ulcers per patient up to Week 24
Time frame: 24 weeks
Change from baseline to Week 24 in hand pain
Pain assessed on visual analog scales
Time frame: Baseline and Week 24
Change from baseline to Week 24 in hand disability
Hand disability indexed assessed using the Health Assessment Questionaire (HAQ)
Time frame: Baseline and Week 24
Proportion of subjects with treatment-emergent adverse events
Time frame: up to 32 weeks (8 week post-treatment follow-up)
Proportion of subjects with liver function abnormalities
Increase in aminotransferases
Time frame: Every 4 weeks up to Week 24
No study locations are listed for this record.
The record gives a start of Oct 2003, a primary completion of Mar 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan